Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma
GlaxoSmithKline
Vania Hungria; Pawel Robak; Marek Hus; Vera Zherebtsova; Christopher Ward; P Joy Ho; Ana Carolina Ribas de Almeida; Roman Hajek; Kihyun Kim; Sebastian Grosicki; Hanlon Sia; Adam Bryant; Marcelo Pitombeira de Lacerda; Gracia Aparecida Martinez; Anna Maria Sureda Balarí; Irwindeep Sandhu; Claudio Cerchione; Peter Ganly; Meletios Dimopoulos; Chengcheng Fu; Mamta Garg; Al-Ola Abdallah; Albert Oriol; Moshe E Gatt; Michele Cavo; Robert Rifkin; Tomoaki Fujisaki; Michał Mielnik; Nick Pirooz; Astrid McKeown; Simon McNamara; Xiangdong Zhou; Maureen Nichols; Eric Lewis; Rachel Rogers; Hena Baig; Lydia Eccersley; Sumita Roy-Ghanta; Joanna Opalinska; María-Victoria Mateos; DREAMM-7 Investigators